MGCD treatment inhibited HDACs, enhanced miR‐133a, and decreased the levels of α‐SMA and COL1α‐2, leading to reduced renal fibrosis/remodeling and lowered BP in the mutant animals (Figure 10). Here, COL1A2 is linked to renal fibrosis.